Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review

This conference poster presented at the CHIC Symposium shows findings from a scoping review of financing mechanisms for human papillomavirus (HPV) vaccination in Africa. The review maps existing evidence on HPV vaccine financing across the region to identify funding sources, cost estimates, and key challenges to sustainable financing.  The analysis synthesizes evidence on funding mechanisms, delivery costs, cost drivers, willingness to pay, and cost-effectiveness considerations relevant to HPV vaccination programs in Africa.

Key findings / insights

• Approximately 68% of countries rely on donor funding—primarily Gavi—for HPV vaccine financing, sometimes supplemented by other partners such as WHO or national ministries of health.
• Financial delivery costs range from US$0.27 to US$19.76, while economic costs range from US$3.09 to US$91.19, depending on country context, vaccine type, and delivery strategy. 
• Major cost drivers include service delivery, personnel costs, social mobilization, information materials, and outreach to out-of-school girls.
• Evidence suggests that single-dose HPV vaccination schedules reduce financial and logistical costs while maintaining comparable efficacy.
• School-based delivery approaches can be cost-effective in several contexts, while facility-based delivery may be cheaper in others.
• Studies show 91.6% of mothers were willing to pay approximately US$11.68 per fully vaccinated girl, although this is lower than the Gavi-subsidized vaccine cost.
• Key challenges include heavy reliance on external donors, limited local economic evidence for planning, high delivery costs, and constrained national health budgets. 

Thumbnail image credit: Gavi